C3491974||Asunaprevir
C4049839||HCV Protease Inhibitor
C0023884||Liver
C1378698||Distribution
C3491974||Asunaprevir
C4049839||inhibitor of the hepatitis C virus (HCV) NS3/4A protease
C0008972||clinical studies
C0439663||infected
C3532919||HCV genotype 1
C3532922||4
C0982327||peginterferon
C0035525||ribavirin
C0013162||combinations
C1378698||preferential distribution
C3491974||asunaprevir
C0023884||liver
C0949791||organic anion-transporting polypeptide
C0949791||organic anion-transporting polypeptide
C3491974||asunaprevir
C0226896||oral
C3491974||Asunaprevir
C0035608||rifampin
C0949791||organic anion-transporting polypeptide
C0080105||subjects
C0948807||hepatic impairment
C3491974||asunaprevir
C0080105||subjects
C0439663||infected
C0220847||hepatitis C virus
C1708335||healthy subjects
C0078988||Asian
C0080105||subjects
C0080105||whites
C0205054||hepatic
C0002594||transaminase
C0151625||abnormalities
C0205054||hepatic
C1515655||in vivo
C0201734||pharmacokinetic
C1709518||pharmacodynamic
C0872152||development